Author Archives: Vijaya Iyer, PhD

Proton Radiation Therapy Improves Survival in Lung Cancer Patients with IPF, Study Finds

Lung cancer patients with underlying idiopathic pulmonary fibrosis (IPF) treated with proton radiation therapy live longer than those treated with X-ray irradiation, a study shows. Additionally, fewer occurrences of treatment-related lung complications were reported in proton therapy-treated patients. The study, “Preliminary result of definitive radiotherapy in patients with non-small cell…

Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status

Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…

Phase 2 Trial Now Underway to Test Galapagos’ GLPG1205 in IPF Patients

Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…